Galenica : Quality comes at a price
Galenica is a well-managed and resilient company that has an unassailable dominance of the Swiss pharma distribution and related services. Over the years the company has earned a quality compounder reputation (+12% annualised TRS since IPO) which is reflected in its 20% average premium vs the SMI. Going forward we expect the company to keep a robust TRS profile of 8-9% p.a. (ex M&A). We initiate our coverage with a Neutral rating as its current premium (30%) and the limited upside to our target valuation (<5%) cannot sustain a more positive opinion.Galenica AG, previously Galenica Sante Ltd, is a Switzerland-based healthcare services and products provider. The Company's business i divided into three business sectors: Retail, Products & Brands, and Services. The Company manages a locally established pharmacies network in Switzerland. It develops and distributes its own product portfolio, as well as cooperates with a range of business partners, such as Pierre Fabre, Ales Groupe and Vitor Consumer Health for marketing and distribution of such brands as Perskindol, Triofan, A-Derma, Lierac, Phyto, Anti-Brumm and Algifor. Galenica Sante's Services business sector is responsible for management of such logistics sector companies as Galexis, Unione Farmaceutica Distribuzione, Alloga and Medifilm.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.